PCYC-1141-CA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab Versus Placebo in Combination With Rituximab in Treatment Naive Subjects With Follicular Lymphoma
More Information
PRISM
PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma (ACE-LY-111)
More Information
ACE-LY-003
An Open-Label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-Cell Non-Hodgkin Lymphoma
More Information
Alliance A051301
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
More Information
S1318
A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients > 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia
More Information
S1608
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
More Information
SGN35-028
A Phase 2, Multicenter, Single-Arm Study of Retreatment with Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-Expressing Peripheral T-Cell Lymphoma (PTCL)
More Information
ICP-CL-00107
A Phase I, Multicenter, Open-Label, Dose Escalation Study of a Novel Bruton’s Tyrosine Kinase Inhibitor, ICP-022, in Patients with Relapsed/Refractory B-Cell Malignancies.
More Information